SEARCH:   Advanced

Blood, 9 April 2009, Vol. 113, No. 15, pp. 3604-3611. Prepublished online as a Blood First Edition Paper on February 3, 2009; DOI 10.1182/blood-2008-08-175323. This Article Full Text (PDF) All Versions of this Article: blood-2008-08-175323v1 113/15/3604    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pulsipher, M. A. Articles by Confer, D. L. Search for Related Content PubMed PubMed Citation Articles by Pulsipher, M. A. Articles by Confer, D. L. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 21, 2008 Accepted January 22, 2009 Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the National Marrow Donor Program Michael A. Pulsipher*, Pintip Chitphakdithai, John Miller, Brent R. Logan, Roberta J. King, J. Douglas Rizzo, Susan F. Leitman, Paolo Anderlini, Michael Haagenson, Seira Kurian, John P. Klein, Mary M. Horowitz, and Dennis L. Confer University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, UT, United States Center for International Blood and Marrow Transplant Research, Minneapolis, MN, United States National Marrow Donor Program, Minneapolis, MN, United States Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States National Institutes of Health, Clinical Center, Bethesda, MD, United States University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Los Angeles County Department of Public Health, Los Angeles, CA, United States * Corresponding author; email: michael.pulsipher{at}hsc.utah.edu. Limited data are available describing donor adverse events (AE) associated with filgrastim mobilized Peripheral Blood Stem Cell (PBSC) collections in unrelated volunteers. We report results in 2408 unrelated PBSC donors prospectively evaluated by the National Marrow Donor Program (NMDP) between 1999 and 2004. Female donors had higher rates of AE, requiring central line placement more often (17% vs. 4%, p<0.001), experiencing more apheresis related AE (20% vs. 7%, p<0.001), more bone pain (odds ratio (OR)=1.49), and higher rates of grades II-IV and III-IV CALGB AE (OR=2.22 and 2.32). Obese donors experienced more bone pain (obese vs. normal OR=1.73) and heavy donors had higher rates of CALGB toxicities (>95 kg vs. <70 kg, OR=1.49). Six percent of donors experienced grade III-IV CALGB toxicities and 0.6% experienced toxicities that were considered serious and unexpected. Complete recovery is universal, however, and no late AE attributable to donation have been identified. In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donors will experience bone pain, one in four will have significant headache, nausea or citrate toxicity, and a small percentage will experience serious short-term adverse events. In addition, women and larger donors are at higher risk for donation-related AE. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020